Risk Management Shines Light on ICH Q12 Use for Biologics
![World Management World Management](/images/default-source/default-album/pda-letter/new-portal/articles/july-august-2018/world-management.jpg?sfvrsn=e84f8a8e_0)
Wanting pharma companies to consider quality-by-design (QbD) elements throughout a product’s entire lifecycle, including post-approval changes, through integration of risk- and knowledge-based approaches, seems to have become a global regulatory expectation. For biologics, however, using these approaches is more complex and companies cannot simply adopt the same strategies used for traditional small molecules.